A paradigm shift for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2−) advanced breast cancer: a review of CDK inhibitors

In the last 3 years, a novel class of targeted therapy has been approved for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2−) breast cancer. There are currently three approved agents, which are oral cyclin-dependent kinase 4/6 (CDK4/6) inhibitors...

Descripción completa

Detalles Bibliográficos
Autores principales: Fernandes, Mariane Teodoro, Adashek, Jacob J, Barreto, Carmelia Maria Noia, Spinosa, Ana Cláudia Barbin, de Souza Gutierres, Barbara, Lopes, Gilberto, del Giglio, Auro, Aguiar, Pedro Nazareth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioExcel Publishing Ltd 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6220897/
https://www.ncbi.nlm.nih.gov/pubmed/30416529
http://dx.doi.org/10.7573/dic.212555

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6220897/
https://www.ncbi.nlm.nih.gov/pubmed/30416529
http://dx.doi.org/10.7573/dic.212555

Ejemplares similares